Freda, Christopher Thor
Yin, Wei
Ghebrehiwet, Berhane
Rubenstein, David A. http://orcid.org/0000-0002-9495-9049
Article History
Received: 8 April 2021
Accepted: 5 August 2021
First Online: 31 August 2021
Conflict of interest
: Berhane Ghebrehiwet receives royalties from the sale of monoclonal antibodies against gC1qR clone 60.11. Berhane Ghebrehiwet holds a patent for the development of these antibodies for therapy against angioedema, respectively (US patent 8,883,153-B2, “Methods for Prevention and Treatment of Angioedema”) as well as against cancer. Christopher T. Freda, Wei Yin and David A. Rubenstein declare that they have no conflict of interest.
: No human studies were carried out by the authors for this article. No animal studies were carried out by the authors for this article.
Free to read: This content has been made available to all.